Correction Notice: Stock Option Exercise Price Adjustment and Increase in Granted Shares

Genome & Company filed a correction to the stock option grant report dated March 29, 2021.
Granted shares: increased from 6,000 to 8,500 (increase of 2,500 shares).
Exercise price: reduced from 50,490 won to 14,230 won (approx. 72% decrease).
Total outstanding options: increased from 1,941,396 to 4,092,568 shares.
Reason: adjustment due to capital increases (paid-in and stock dividends) and cancellations from resignations.
Fair value method: binomial model with volatility 60.90%, risk-free rate 0.50~2.63%.
Exercise period: 2023.03.30 ~ 2030.03.29.